Why technology standards are critical for Quantum-Safe Security

Posted by Mark Pecen | October 26, 2017

Safeguard Insights

September 1, 2011

NuPathe: FDA CRL Doesn’t Reject NDA or Impact Potential Long-Term Value, Only Delays Launch

The line between long-term value creation and short-term speculative trading was never as stark as it was this week on Tuesday, August 30, after life…

Posted by John E. Shave III
August 26, 2011

Week in Review: Apple, the FDA, and education

This week, many were surprised by the news coming out of Silicon Valley as the famed entrepreneur Steve Jobs stepped down as Apple’s CEO on…

Posted by John E. Shave III
June 27, 2011

Safeguard Scientifics Leads $35 Million Financing for NovaSom

Baltimore-based company provides home sleep tests for the diagnosis of obstructive sleep apnea Wayne, PA, June 27, 2011 – Safeguard Scientifics, Inc. (NYSE: SFE), a holding…

Posted by James A. Datin
March 3, 2011

Safeguard Scientifics Fourth Quarter and Year-End Financial Results Recap, Highlighting Aggregate Partner Company Revenue Growth, Acquisitions and IPOs

This morning, we announced our fourth quarter and year-end 2010 financial results. In 2010, our aggregate partner company revenue was $403 million, up 54 percent…

Posted by John E. Shave III
November 1, 2010

NuPathe Submits Zelrix NDA for the Treatment of Migraine

Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…

Posted by James A. Datin
Content

Most Popular Posts